Clinical trial
UMD rPA Regimen Trial in Adults
NCT00133484 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Terminated
Key facts
| NCT number | NCT00133484 |
|---|---|
| Title | UMD rPA Regimen Trial in Adults |
| Official title | A Phase II Study to Assess the Safety, Tolerability, Immunogenicity, and Optimal Primary Schedule of 3 Recombinant Protective Antigen (rPA) Anthrax Vaccines Administered in Two Intramuscular Doses to Healthy Adults |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bacillus Anthracis (Anthrax) |
| Intervention type | Biological |
| Interventions | Anthrax vaccine absorbed made from Bacillus anthracis (AVA), Recombinant protein antigen (rPA) made from Bacillus anthrax, Recombinant protein antigen (rPA) made from Escherichia coli |
| Enrollment | 270 |
| Completion | May 1, 2007 |
| First posted | Aug 23, 2005 |
| Last update posted | Aug 27, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: